Oryzon to provide corporate progress updates at several events in June

Oryzon Genomics S.A., Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in June. 

Oryzon will attend BIO International 2024, which will be held at the San Diego Convention Center in San Diego (USA) on June 3-6, where the company will hold one-on-one meetings with pharmaceutical companies and global al investors. Click on the link for more info about BIO International Convention 2024. 

Oryzon will present preliminary results from the ongoing FRIDA study, which is evaluating iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia harboring a FLT3 mutation, at the European Hematology Association (EHA) 2024 congress, to be held at the IFEMA Recinto Ferial in Madrid (Spain) on June 13-16. The data will be disclosed as a poster communication entitled “Preliminary results of the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML”, to be presented by Dr. Amir Fathi, from the Massachusetts General Hospital and Principal Investigator of the study, on June 14. Click on the link for more info about EHA2024. 

Oryzon will attend the European Network to Cure ALS (ENCALS) 2024 meeting, which will take place at the Karolinska Institutet in Stockholm (Sweden) on June 17-20. Click on the link for more info about ENCALS 2024.